The goal of this clinical trial is to learn if Stereotactic Body Radiotherapy (SBRT) can treat the oligo-progressive metastatic non-small cell lung cancer (NSCLC) after first-line chemotherapy. The main questions it aims to answer are:
Does SBRT improve progression-free survival in oligo-progressive metastatic non-small cell lung cancer after first-line chemotherapy? Does SBRT improve overall survival and quality of life in oligo-progressive metastatic non-small cell lung cancer after first-line chemotherapy?
Researchers will compare SBRT in combination with standard of care (SOC) and SOC only to see if SBRT works to treat oligo-progressive metastatic non-small cell lung cancer after first-line chemotherapy.
Participants will:
Take SBRT in combination with SOC or SOC only. Visit the clinic for checkups and tests as required by the study. Keep a diary of their symptoms and complete the quality of life assessment questionnaire.
Age ≥ 18 years. Gender is not limited.
Histologically and/or cytologically confirmed stage IV metastatic NSCLC.
Eastern Cooperative Oncology Group (ECOG) score of 0-2.
Patients who had prior first-line chemotherapy with clinical benefit lasting for ≥3 months.
Currently participating in an interventional clinical study treatment that may affect this study, or have been treated with another investigational drug or investigational device that may affect this study within 4 weeks prior to first treatment.
Pregnant or lactating women.
Progression sites deemed unsuitable for SBRT treatment as assessed by radiotherapy specialists.
Presence of untreated intracranial metastases or symptomatic progressive sites.